Oxford’s PRINCIPLE Trial: Ivermectin Being Considered as Part of the Study

The University of Oxford soon kicks “the PRINCIPLE Trial” into a higher gear now, in what they consider a pathbreaking “high-quality trial” that may consider the generic drug Ivermectin. The UK government also backs this pivotal study via the Department of Health and Social Care. Searching for early-onset, home-based ambulatory treatments for COVID-19, the PRINCIPLE Trial seeks to meet a gap in research in the world’s richest nations to date. Nearly all of the taxpayer-financed research-based expenditures of governments in the US, UK and Europe, for example, have gone into vaccines, novel monoclonal antibodies, and novel therapeutics, with an emphasis on treating severely ill patients. The preeminent University of Oxford and the PRINCIPLE Trial: the globe’s top investigators now seek to possibly test if Ivermectin and antiviral Favipiravir, both low-cost, orally-administered, generally available generic drugs, can be proven safe and effective in a “properly designed trial.” Led by Co-Chief investigator Chris Butler, Professor of Primary Care, Nuffield Department of Primary Care, Health Services at Oxford, the study team is generally upbeat about the prospects. Still, Dr. Butler no...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee